[Safety and feasibility of laparoscopic double-flap technique in digestive tract reconstruction after proximal gastrectomy for esophagogastric junction tumors larger than 5 cm] [0.03%]
[远端食管胃结合部肿瘤>5cm患者近端胃切除术后消化道重建的 Laparoscopy Double-Flap 技术安全性和可行性分析]
X F Zhu,W W Xiong,Y S Zheng et al.
X F Zhu et al.
Objective: To investigate the safety and feasibility of laparoscopic double-flap technique (Kamikawa) in digestive tract reconstruction after proximal gastrectomy for esophagogastric junction (EGJ) leiomyoma and gastrointestinal stromal tum...
[Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment] [0.03%]
新辅助治疗胃癌患者的术后并发症及其对预后因素的影响分析
T B Wang,Q K Mao,X J Zhang et al.
T B Wang et al.
Objective: To investigate postoperative complications of patients undergoing neoadjuvant therapy followed by radical gastrectomy, and to analyze their influence on the prognosis. Methods: A retrospective case-control study was used. Case in...
[Risk factors of postoperative complication after total gastrectomy in advanced gastric cancer patients receiving neoadjuvant chemotherapy] [0.03%]
新辅助化疗晚期胃癌全胃切除术后并发症的风险因素分析
H Cui,K C Zhang,B Cao et al.
H Cui et al.
Objective: At present, there are few studies focusing on the factors short-term complications after total gastrectomy in patients with advanced gastric cancer receiving neoadjuvant chemotherapy (NACT). The purpose of this study is to provid...
[Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection] [0.03%]
奥沙利铂与S-1新辅助化疗治疗D2根治术后局部进展期胃癌患者的安全性及有效性研究
Y D Bao,H Zhang,L Dong et al.
Y D Bao et al.
Objective: To investigate the safety and efficacy of oxaliplatin combined with S-1 (SOX) as adjuvant chemotherapy after D2 radical gastrectomy for locally advanced gastric cancer. Methods: A descriptive case series study was applied. Case i...
[Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer] [0.03%]
奥沙利铂联合卡培他滨与奥沙利铂联合苏特里作为胃癌新辅助化疗的临床安全性和有效性研究
B W Xie,L Zang,J J Ma et al.
B W Xie et al.
Objective: To explore the safety and efficacy of oxaliplatin plus capecitabine (CapeOX) or oxaliplatin plus S-1 (SOX) regimen neoadjuvant chemotherapy in the treatment of advanced gastric cancer. Methods: A retrospective cohort study was pe...
[Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial] [0.03%]
[Siewert II和III型食管胃交界部腺癌新辅助化学放射治疗联合手术与直接手术的长期预后对比：一项前瞻性随机对照试验]
Y Tian,Q Wang,J Wang et al.
Y Tian et al.
Objective: To investigate the effectiveness, safety, and prognosis of neoadjuvant chemoradiotherapy (nCRT) for Siewert type II and III adenocarcinomas of the esophagogastric junction (AEG). Methods: This study is a prospective randomized co...
Y B Zhou
Y B Zhou
Gastrointestinal cancer and related treatments (surgery and chemoradiotherapy) are associated with declined functional status (FS) that has impact on quality of life, clinical outcome and continuum of care. Psychological distress drives an ...
[Implementation strategy of enhanced recovery after surgery in perioperative management of gastric cancer] [0.03%]
胃癌围手术期管理中加速康复外科的实施策略
C Yan,Z Y Li
C Yan
Enhanced recovery after surgery (ERAS) has deeply influenced the clinical practice of surgery, anesthesia and nursing since its inception in 1997. The successful implementation of perioperative ERAS in gastric cancer depends on continually ...
[Exploration and thoughts on perioperative treatment of advanced gastric cancer] [0.03%]
[进展期胃癌围手术期治疗的探索与思考]
Y F Li,Z W Zhou
Y F Li
Perioperative treatment is critical to improve the outcomes of patients with advanced gastric cancer. There are three therapeutic modes of perioperative treatment for resectable gastric cancer: neoadjuvant chemotherapy+ D1/D2 surgery+ adjuv...
H Liang
H Liang
Gastric cancer is one of the most common malignancy in China. Most of the patients of gastric cancer treated clinically are in advanced stage. In the past years, with the progress of anti-cancer drug therapy, after the comprehensive treatme...